Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in non–small cell lung cancer-Reference-Cited by-同舟云学术

Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in non–small cell lung cancer

Published:2022-07-18 Issue:9 Volume:113 Page:3148-3160
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Nakahama Kenji¹^ORCID,Kaneda Hiroyasu²,Osawa Masahiko³,Fukui Mitsuru⁴,Izumi Motohiro⁵,Yoshimoto Naoki⁶,Sugimoto Akira⁷,Nagamine Hiroaki⁷,Ogawa Koichi⁷,Matsumoto Yoshiya⁷,Sawa Kenji⁷,Tani Yoko²,Mitsuoka Shigeki²,Watanabe Tetsuya⁷,Asai Kazuhisa⁷,Kawaguchi Tomoya²⁷

Affiliation:

1. Department of Respiratory Medicine Osaka City University, Graduate School of Medicine Osaka Japan

2. Department of Clinical Oncology Osaka Metropolitan University, Graduate School of Medicine Osaka Japan

3. Department of Diagnostic Pathology Osaka Metropolitan University, Graduate School of Medicine Osaka Japan

4. Department of Laboratory of Statistics Osaka Metropolitan University, Graduate School of Medicine Osaka Japan

5. Department of Pulmonary Medicine Bell land General Hospital Sakai Japan

6. Department of Pulmonary Medicine Ishikiriseiki Hospital Higashiosaka Japan

7. Department of Respiratory Medicine Osaka Metropolitan University, Graduate School of Medicine Osaka Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15464

Reference43 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

3. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

4. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

5. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer